Why these two injections treat different problems

Deciding between ChondroFiller and hyaluronic acid (HA) starts with a scan result, not a product comparison. These two injections treat fundamentally different conditions — reaching for the wrong one offers little clinical value, regardless of how well-reviewed it is for its intended use.

ChondroFiller is a collagen scaffold placed under ultrasound guidance into a focal, discrete cartilage lesion — typically Grade III or IV, up to 6 cm², confirmed on MRI. Its purpose is biological: the scaffold promotes the body's own repair processes by recruiting the patient's progenitor cells into the damaged area.

HA viscosupplements work differently and for a different patient. They replenish degraded synovial fluid across a broadly worn joint, reducing friction-related pain in mild-to-moderate osteoarthritis. They do not repair cartilage tissue.

Conflating the two as rival treatments for the same condition is a clinical error flagged explicitly by specialists in this field. A patient with a contained focal defect is not a straightforward HA candidate; a patient with diffuse early-to-moderate osteoarthritis and no discrete lesion is unlikely to benefit from ChondroFiller.

The starting point, in either case, is imaging and a specialist assessment — not product preference.

How ChondroFiller works as an injectable scaffold

The product itself is a two-component Type I collagen hydrogel — CE-marked as a Class III medical device, the highest implantable tier in European regulation, and derived from murine collagen. It arrives at the clinic as a liquid and is placed inside the cartilage defect through an ultrasound-guided outpatient injection, with no general anaesthetic or surgical incision involved.

Once inside the cavity, the gel self-sets within approximately 3–5 minutes, conforming to the contours of the defect and forming a stable three-dimensional fibrillar matrix. That physical structure is the starting point for the repair process.

The biological mechanism is known as acellular matrix-induced chondrogenesis — in plain terms, the scaffold creates a hospitable environment that draws the patient's own progenitor cells, migrating in from the surrounding synovium and subchondral bone, into the lesion. No cells are injected; the body supplies them. A 2025 ex vivo study confirmed this, recording a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14, consistent with active cell recruitment.

One practical consideration follows from the gel's early state: a 2024 biomechanical study found that before stable integration is achieved, the gel cannot adequately protect the opposing cartilage surface under cyclic load. Post-injection weight-bearing restriction is therefore a standard part of the recovery plan — something a treating specialist will outline at the assessment stage.

What the clinical evidence for ChondroFiller shows

The clinical outcome data for ChondroFiller spans several joints and study designs, though the evidence base is still developing and sample sizes remain small — points worth stating plainly rather than burying.

For the knee, a prospective study published in JIMAB (2024) followed 17 patients with a mean age of 31. Both Lysholm and IKDC scores — validated measures of knee function and symptoms — improved significantly at 3, 6, and 12 months post-procedure (p<0.05), with gains plateauing between six and twelve months rather than continuing to climb. The first randomised controlled trial, published in 2016 and comparing ChondroFiller against microfracture (13 versus 10 patients), demonstrated significant IKDC improvement at the same time points. MRI MOCART scores — a standardised grading of how well new tissue integrates with the surrounding cartilage — indicated good defect filling shortly after treatment and progressive maturation by 52 weeks, with no adverse events recorded in either group.

The hip dataset is as instructive for patient selection as it is for outcomes. A cohort study (n=26, follow-up 12–60 months) found 17 of 21 evaluable patients achieved good or excellent results at three to five years. Patients with pre-existing osteoarthritis rated Tönnis grade 2–3, however, did poorly — establishing OA severity as a firm exclusion criterion. ChondroFiller addresses focal defects; it is not indicated where significant background joint degeneration is already present.

A 2025 wrist study broadens the picture further. Among 25 patients treated following intra-articular distal radius fractures, follow-up arthroscopy recorded significantly better cartilage quality than untreated controls (Outerbridge score 1.5 versus 3, p=0.006).

Taken together, the available studies show consistently positive functional signals across multiple joints. What they do not yet provide is the larger-scale, longer-term RCT data needed to draw firmer conclusions — a limitation any patient or clinician should factor into their assessment.

How hyaluronic acid works and what its evidence shows

Viscosupplementation — a gel injection that supplements the joint's natural fluid — works on a fundamentally different principle from a scaffold approach. Hyaluronic acid (HA) is injected into the joint space to replenish synovial fluid that has thinned or degraded in an osteoarthritic joint, reducing friction and easing pain across a broadly affected surface. It does not create structural cartilage repair.

The mechanism was long described as purely mechanical, but a 2026 narrative review suggests efficacy may owe more to biological viscoinduction — longer-term cellular and molecular changes stimulated by HA — than to lubrication alone. That same review confirms moderate, durable improvements in pain and function lasting up to six months, with outcomes superior to corticosteroids over the medium-to-long term. The patient phenotype most likely to benefit is a non-obese individual with early-to-moderate osteoarthritis (Kellgren-Lawrence grades I–III).

The 2024 EUROVISCO consensus guidelines reflect a broadly supportive position, recommending HA across all age groups in symptomatic knee OA, including patients with diabetes, moderate obesity, gout, or mild-to-moderate malalignment. Use is advised against during an OA flare or in pregnancy.

Set against that, a 2026 systematic review published in Australian Prescriber reaches a more cautionary conclusion: most major clinical guidelines conditionally recommend against HA for knee OA, on the grounds that randomised trial evidence shows no clinically important benefit. The review also flags potential serious harms, including septic arthritis and severe inflammatory reactions, noting a substantial gap between guideline guidance and prescribing practice.

Both positions are represented in current literature. A specialist assessment is the appropriate place to weigh HA against individual circumstances.

Which patients suit each injection — and who suits neither

The clearest cases map straightforwardly: a younger patient with an MRI-confirmed focal lesion and no meaningful background degeneration, or an older patient with diffuse, bilateral joint aching that has developed gradually over years. The harder question — and the one that genuinely warrants its own section — is what happens when those profiles overlap.

That grey zone is where outcome data offers the sharpest practical guidance. The hip cohort study discussed earlier found that patients with Tönnis grade 2–3 osteoarthritis fared poorly with ChondroFiller even where a focal lesion was present. The scaffold requires a reasonably intact joint environment to function as intended; once background degeneration crosses a threshold, biological repair of one isolated patch is unlikely to resolve symptoms that originate from the wider joint. A comparable ceiling applies at the HA end: evidence suggests benefit diminishes substantially in advanced disease where structural damage is no longer focal or mild.

For borderline presentations, the tipping signal is not symptom severity or duration but the combination of MRI morphology and OA grading. A Kellgren-Lawrence grade II knee with a single contained Grade III lesion may be assessed for ChondroFiller if that defect is the dominant pain source; the same joint managed primarily as osteoarthritis would be an HA candidate. Determining which problem is driving symptoms — and whether the two problems can even be separated — requires specialist review. No symptom pattern reliably makes that distinction in mixed presentations.

Where a focal defect and moderate background OA coexist, some patients are assessed for a combination approach. These decisions are individually determined; the choice of pathway is not one patients can safely reach without imaging and clinical assessment.

Finding a specialist who offers ChondroFiller or HA injection

The practical question at this stage is what to bring to a first consultation rather than which injection to request. Two things worth establishing early: whether the lesion type and grade have already been confirmed on prior scanning, and which pathway — regenerative scaffold, viscosupplementation, or something else — the specialist considers appropriate given that picture. A clinician who can assess both options in the same appointment is well placed to answer both questions rather than routing the patient toward a product before the diagnosis is settled.

Both ChondroFiller injection and HA viscosupplementation are available from MSK specialists across the UK as ultrasound-guided outpatient treatments. Search MSK lists clinicians with cartilage-focused injection expertise — searchable by region and specialty — which can help identify one whose practice covers both pathways and can tailor the recommendation to the underlying diagnosis.